Literature DB >> 27883178

Genotype-phenotype correlation in 44 Czech, Slovak, Croatian and Serbian patients with mucopolysaccharidosis type II.

L Dvorakova1, H Vlaskova1, A Sarajlija2,3, D P Ramadza4, H Poupetova1, E Hruba1, A Hlavata5, V Bzduch6, K Peskova1, G Storkanova1, B Kecman2, M Djordjevic2,3, I Baric7, K Fumic8, I Barisic9, M Reboun1, J Kulhanek10, J Zeman1,10, M Magner10.   

Abstract

Mucopolysaccharidosis type II (Hunter syndrome, MPS II, OMIM 309900) is an X-linked lysosomal storage disorder caused by deficiency of iduronate-2-sulfatase (IDS). We analyzed clinical and laboratory data from 44 Slavic patients with this disease. In total, 21 Czech, 7 Slovak, 9 Croatian and 7 Serbian patients (43 M/1 F) were included in the study (median age 11.0 years, range 1.2-43 years). Birth prevalence ranged from 1:69,223 (Serbia) to 1:192,626 (Czech Rep.). In the majority of patients (71%), the disease manifested in infancy. Cognitive functions were normal in 10 patients. Four, six and 24 patients had mild, moderate, and severe developmental delay, respectively, typically subsequent to developmental regression (59%). Residual enzyme activity showed no predictive value, and estimation of glycosaminoglycans (GAGs) had only limited importance for prognosis. Mutation analysis performed in 36 families led to the identification of 12 novel mutations, eight of which were small deletions/insertions. Large deletions/rearrangements and all but one small deletion/insertion led to a severe phenotype. This genotype-phenotype correlation was also identified in six cases with recurrent missense mutations. Based on patient genotype, the severity of the disease may be predicted with high probability in approximately half of MPS II patients.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Hunter syndrome; MPS II; Slavic origin; genotype-phenotype correlation; mucopolysaccharidosis type II

Mesh:

Substances:

Year:  2017        PMID: 27883178     DOI: 10.1111/cge.12927

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  7 in total

1.  Dose-dependent effects of a brain-penetrating iduronate-2-sulfatase on neurobehavioral impairments in mucopolysaccharidosis II mice.

Authors:  Hideto Morimoto; Hiroki Morioka; Atsushi Imakiire; Ryuji Yamamoto; Tohru Hirato; Hiroyuki Sonoda; Kohtaro Minami
Journal:  Mol Ther Methods Clin Dev       Date:  2022-05-10       Impact factor: 5.849

2.  Clearance of heparan sulfate in the brain prevents neurodegeneration and neurocognitive impairment in MPS II mice.

Authors:  Hideto Morimoto; Sachiho Kida; Eiji Yoden; Masafumi Kinoshita; Noboru Tanaka; Ryuji Yamamoto; Yuri Koshimura; Haruna Takagi; Kenichi Takahashi; Tohru Hirato; Kohtaro Minami; Hiroyuki Sonoda
Journal:  Mol Ther       Date:  2021-01-26       Impact factor: 11.454

Review 3.  Detection of Structural Variants by NGS: Revealing Missing Alleles in Lysosomal Storage Diseases.

Authors:  Valentina La Cognata; Sebastiano Cavallaro
Journal:  Biomedicines       Date:  2022-07-29

4.  Treatment of mucopolysaccharidosis type II (Hunter syndrome): a Delphi derived practice resource of the American College of Medical Genetics and Genomics (ACMG).

Authors:  Kim L McBride; Susan A Berry; Nancy Braverman
Journal:  Genet Med       Date:  2020-08-03       Impact factor: 8.822

5.  Functional assessment of the genetic findings indicating mucopolysaccharidosis type II in the prenatal setting.

Authors:  Maria Fuller; David Ketteridge
Journal:  JIMD Rep       Date:  2021-03-26

6.  Estimated prevalence of mucopolysaccharidoses from population-based exomes and genomes.

Authors:  Pâmella Borges; Gabriela Pasqualim; Roberto Giugliani; Filippo Vairo; Ursula Matte
Journal:  Orphanet J Rare Dis       Date:  2020-11-18       Impact factor: 4.123

7.  Therapy-type related long-term outcomes in mucopolysaccaridosis type II (Hunter syndrome) - Case series.

Authors:  Mojca Zerjav Tansek; Jana Kodric; Simona Klemencic; Jaap Jan Boelens; Peter M van Hasselt; Ana Drole Torkar; Maja Doric; Alenka Koren; Simona Avcin; Tadej Battelino; Urh Groselj
Journal:  Mol Genet Metab Rep       Date:  2021-06-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.